IP Verse

New Use - EP3626270

The patent EP3626270 was granted to Novartis on Oct 11, 2023. The application was originally filed on Aug 26, 2014 under application number EP19202854A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3626270

NOVARTIS
Application Number
EP19202854A
Filing Date
Aug 26, 2014
Status
Granted And Under Opposition
Sep 8, 2023
Grant Date
Oct 11, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (17)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELPEN PHARMACEUTICALJul 11, 2024HASELTINE LAKE KEMPNERADMISSIBLE
GENERICS UKJul 11, 2024ELKINGTON AND FIFEADMISSIBLE
LANYON OPPOSITIONSJul 11, 2024PINSENT MASONSADMISSIBLE
ZENTIVA KSJul 11, 2024GREINERADMISSIBLE
BULLE DRJul 10, 2024KUTZENBERGER WOLFF & PARTNERADMISSIBLE
CAMULONJul 10, 2024REDDIE & GROSEADMISSIBLE
DR SCHONJul 10, 2024DR SCHONADMISSIBLE
POLPHARMAJul 10, 2024HAMM & WITTKOPPADMISSIBLE
SYNTHONJul 10, 2024HOFFMANN EITLEADMISSIBLE
TEVA PHARMACEUTICALSJul 10, 2024D YOUNGADMISSIBLE
WUESTHOFF & WUESTHOFFJul 10, 2024SONNENHAUSERADMISSIBLE
HOFFMANN EITLEJul 9, 2024HOFFMANN EITLEWITHDRAWN
EGISJul 8, 2024STOLMAR & PARTNERADMISSIBLE
HAMM & WITTKOPPJul 5, 2024HAMM & WITTKOPPADMISSIBLE
HAMM & WITTKOPPJul 5, 2024HAMM & WITTKOPPWITHDRAWN
BETAPHARM ARZNEIMITTELJul 2, 2024HAMM & WITTKOPPADMISSIBLE
ALFRED E TIEFENBACHERJun 25, 2024HAMM & WITTKOPPADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0443983
DESCRIPTIONUS5217996
DESCRIPTIONUS5399578
DESCRIPTIONWO03059345
DESCRIPTIONWO2007056546
DESCRIPTIONWO2009061713
DESCRIPTIONWO2014029848
OPPOSITIONUS2013158088
OPPOSITIONWO03059345
OPPOSITIONWO2007056546
OPPOSITIONWO2015028941
SEARCHUS2013158088
SEARCHWO2007056546

Non-Patent Literature (NPL) Citations (111) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- LEVEY ASBOSCH JPLEWIS JB et al., "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group", Ann Intern Med., (19990316), vol. 130, no. 6, pages 461 - 70, XP009189890-
DESCRIPTION- N Engl J Med, (20010000), vol. 345, pages 1667 - 1675-
EXAMINATION- JORDAAN P ET AL, "Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment", SA HEART CONGRESS 2011, (20110101), page 236, XP055780447-
EXAMINATION- KOBALAVA Z. ET AL, "P4409 Clinic blood pressure in stables heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696", EUROPEAN HEART JOURNAL, (20110101), page 788, XP055891073-
EXAMINATION- Z. KOBALAVA ET AL, "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", EUROPEAN HEART JOURNAL, (20110101), vol. 32, no. P4396, P4409, pages 784; - 785; 788, XP055751748-
EXAMINATION- J. J. V. MCMURRAY ET AL, "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC", EUROPEAN HEART JOURNAL, (20120519), vol. 33, no. 14, doi:10.1093/eurheartj/ehs104, ISSN 0195-668X, pages 1787 - 1847, XP055140708
OPPOSITION- Aktories Klaus, Aktories Klaus, Flockerzi Veit, Förstermann Ulrich, Hofmann Franz Bernhard, Allgemeine und spezielle Pharmakologie und Toxikologie, Urban & Fischer, (20050101), pages 92, 422 - 434, ISBN 978-3-437-44490-6, XP093194301-
OPPOSITION- Aktories Klaus, Aktories Klaus, Flockerzi Veit, Förstermann Ulrich, Hofmann Franz Bernhard, "Elemente und Ablauf der klinischen Prüfung ", Allgemeine und spezielle Pharmakologie und Toxikologie, Urban & Fischer, (20050101), pages 92, 422 - 434, ISBN 978-3-437-44490-6, XP093194301-
OPPOSITION- Anonymous, "DIOVAN - HIGHLIGHTS OF PRESCRIBING INFORMATION", (20121001), (20240322), XP093144494-
OPPOSITION- Anonymous, "Diovan (valsartan) Tablets - Statistical Review and Evaluation", FDA, (20020101), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-283S001_Diovan_statr.pdf, XP093195179-
OPPOSITION- Anonymous, "EFFECT OF ENALAPRIL ON MORTALITY AND THE DEVELOPMENT OF HEART FAILURE IN ASYMPTOMATIC PATIENTS WITH REDUCED LEFT VENTRICULAR EJECTION ", The New England Journal of Medicine, (19920903), vol. 327, no. 10, pages 685 - 691, XP093195174-
OPPOSITION- Anonymous, "Entresto - Summary of Product Characteristics", (20151119), (20240404), XP093148148-
OPPOSITION- Anonymous , "Herzinsuffizienz", Anonymous , Mutschler, Geisslinger, Kroemer, Menzel, Ruth, Mutschler - Arzneimittelwirkungen, Stuttgart , Wissenschaftliche Verlagsgesellschaft , (20130101), pages 510,541 - 545, ISBN 978-3-8047-2898-1, XP093148934-
OPPOSITION- Anonymous, "PARADIGM-HF trial stopped early for benefit", European Society of Cardiology The ESC ESC Press Office Press releases, (20040516), pages 1 - 4, European Society of Cardiology The ESC ESC Press Office Press releases, URL: https://www.escardio.org/The-ESC/Press-Office/Press-releases/PARADIGM-HF-trial-stopped-early-for-benefit, (20220117), XP055879620-
OPPOSITION- Anonymous, "Study NCT01035255 Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients with Chronic Heart Failure (PARADIGM-HF)", ClinicalTrials.gov, (20120503), pages 1 - 3, (20210607), XP055810892-
OPPOSITION- Anonymous, "Systolic Heart Failure", (20220614), URL: https://my.clevelandclinic.org/health/diseases/23276-systolic-heart-failure, XP093195490-
OPPOSITION- Anonymous, "This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF)", ClinicalTrials.gov ID NCT01035255, (20140219), ClinicalTrials.gov ID NCT01035255, URL: https://www.clinicaltrials.gov/study/NCT01035255?term=NCT01035255&rank=1&tab=history&a=14%2523version-content-panel, XP093197558-
OPPOSITION- Bochner, Felix; Misan, Gary M. H., "6.4 Antihypertensives", AUSTRALIAN MEDICINES HANDBOOK, Adelaide, SA, Australia, Australian Medicines Handbook, (19980101), pages 6 - 6-57, ISBN 0-646-35326-8, XP055767140-
OPPOSITION- Center For Drug Evaluation And Research, "Diovan (valsartan) Tablets", Statistical Review(s) NDA 20-665/SE1-S016,21-283/Sel-001, (20020123), XP093197696-
OPPOSITION- Chim C. Lang et al., "Targeting the renin-angiotensin-aldosterone system in heart failure", Nature Reviews Cardiology, (2013), vol. 10, XP055788520-
OPPOSITION- D. Albrecht, "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal , (2011), vol. 32, XP055751748-
OPPOSITION- Doust Jenny, Lehman Richard, Glasziou Paul, "The Role of BNP Testing in Heart Failure", American Academy of Family Physicians, (20061201), vol. 74, no. 11, pages 1893 - 1898, XP093197692-
OPPOSITION- Doust Jenny, Lehman Richard, Glasziou Paul, "The role of BNP testing in heart failure", AMERICAN FAMILY PHYSICIAN, American Academy of Family Physicians, US, US , (20060101), vol. 74, no. 11, ISSN 0002-838X, pages 1893 - 1898, XP093195089-
OPPOSITION- Ema, "Entresto®", ANNEX I Summary of Product Characteristics, (20151119), pages 1 - 18, ANNEX I Summary of Product Characteristics, URL: https://www.ema.europa.eu/, XP093197877-
OPPOSITION- Emea, "ICH Topic E 9 Statistical Principles for Clinical Trials Step 5 NOTE FOR GUIDANCE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS", EMEA CPMP/ICH/363/96, (19980901), pages 1 - 37, EMEA CPMP/ICH/363/96, XP093192237-
OPPOSITION- Fda, "Diovan (valsartan) Tablets", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20121001), HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov, XP093194309-
OPPOSITION- Forth W., D. Henschler Und W. Rummel, "Allgemeine und spezielle Pharmakologie und Toxikologie", Allgemeine und spezielle Pharmakologie und Toxikologie, 9., völlig überarbeitete Auflage, München, Jena, URBAN & FISCHER, Elsevier, (20050101), pages 92 - 422-433, XP093040425-
OPPOSITION- Jordaan P, Albrecht D, Feng A, Chandra P, Kobalava# Z, Averkov O, Alexandriya L, Meray I, Moiseev V, , "Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment", SCIENTIFIC ABSTRACTS - SA HEART CONGRESS 2011, (20110101), vol. 8, no. 4, page 236, XP093197561-
OPPOSITION- Jordaan P, Albrecht D, Feng A, Chandra P, Koboleva Z, Averkov O, Alexandriya L, Meray I, Moiseev V, , "Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment", SA Heart Congress 2011, (20110101), vol. 8, no. 4, page 236, XP093194300-
OPPOSITION- Jordaan P, Et Al, "Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment", SA Heart Congress 2011, (20110101), page 236, XP055780447-
OPPOSITION- Julian Segura Jorge Salazar Luis M Ruilope, "Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition", CURRENT OPINION IN INVESTIGATIONAL DRUGS., CURRENT DRUGS, LONDON., GB, GB , (20130701), vol. 22, no. 7, ISSN 0967-8298, pages 915 - 925, XP009174158-
OPPOSITION- Kobalava Z., Et Al, "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term /c treatment with LCZ696 in heart failure patients: effect (8) on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, P4396, (20110101), pages 784 - 785, XP093040441-
OPPOSITION- Kobalava Z., Kovskayay., Meray I., Glovenko A., Moiseev V., Albrecht D, Feng A., Chandra P. Jordaan P., "P4409 Clinic blood pressure in stables heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696", European Heart Journal, (20110101), page 788, XP055891073-
OPPOSITION- Levin Jennifer, "PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results", BIOTECH, (20140331), BIOTECH, URL: https://www.fiercebiotech.com/biotech/paradigm-hf-trial-of-novartis-lcz696-for-chronic-heart-failure-closes-early-based-on, XP093195175-
OPPOSITION- Luchner Andreas, Et Al, "Bedeutung der Herzinsuffizienzmarker BNP und NT-proBNP für die Klinik", Deutsches Arzteblatt, (20031212), vol. 100, no. 50, pages A3314 - A3321, XP055788524-
OPPOSITION- Maggioni, A.P. ; Anand, I. ; Gottlieb, S.O. ; Latini, R. ; Tognoni, G. ; Cohn, J.N. ; the Val-HeFT Investigators, "Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20021016), vol. 40, no. 8, ISSN 0735-1097, pages 1414 - 1421, XP027372571-
OPPOSITION- Mutschler, "Arzneimittelwirkungen. 10th Ed. Passage Chapter 34: Therapie der Herzinsuffizienz", Wissenschaftliche Verlagsgesellschaft, Stuttgart, Stuttgart , (20200101), pages 1 - 2, 435, (20210607), XP055810985-
OPPOSITION- Partarrieu Jacqueline, "PARADIGM-HF trial stopped early for benefit LCZ696 wins head to head comparison with gold standard treatment", ESC - European Society of Cardiology - Press release, (20140516), pages 1 - 3, ESC - European Society of Cardiology - Press release , URL: https://www.escardio.org/The-ESC/Press-Office/Press-releases/PARADIGM-HF-trial-stopped-early-for-benefit#:~:text=The%20trial%20was%20due%20to,that%20was%20overwhelmingly%20statistically%20significant., XP093197700-
OPPOSITION- Philip Rowe, "8 The two-sample t-test (3). False negatives, power and necessary sample sizes", Philip Rowe, Philip Rowe, Essential Statistics for the Pharmaceutical Sciences, Wiley, (20070101), pages 89 - 101, ISBN 978-0-470-03470-5, XP009559183-
OPPOSITION- Royal College Of Physicians, "CHRONIC HEART FAILURE National clinical guideline for diagnosis and management in primary and secondary care", Full version of NICE Clinical Guideline No 108, (20100801), pages 1 - 153, Full version of NICE Clinical Guideline No 108, URL: https://www.ncbi.nlm.nih.gov/books/NBK65340/pdf/Bookshelf_NBK65340.pdf, XP093197874-
OPPOSITION- Royal College Of Physicians, "CHRONIC HEART FAILURE National clinical guideline for diagnosis and management in primary and secondary care", National clinical guideline for diagnosis and management in primary and secondary care (Full version of NICE Clinical Guideline No 108), Royal College Of Physicians, GB, GB, pages 1 - 646, National clinical guideline for diagnosis and management in primary and secondary care (Full version of NICE Clinical Guideline No 108), URL: https://www.ncbi.nlm.nih.gov/books/NBK65340/pdf/Bookshelf_NBK65340.pdf, XP093197874-
OPPOSITION- Valsartan, "Prescribing information for Diovan", VALSARTAN, (20120101), pages 1 - 20, XP093093489-
OPPOSITION- Wehling, Martin; Diener, Hans-Christoph; ; Manns, Michael P. , "2.2 Chronische Herzinsuffizienz", Wehling, Martin; Diener, Hans-Christoph; ; Manns, Michael P. , Martin Wehling, Klinische Pharmakologie: 256 Tabellen, Stuttgart, Georg Thieme Verlag, (20110101), pages 64 - 75, ISBN 978-3-13-126822-8, XP009559091-
OPPOSITION- Yancy Clyde W, Jessup Mariell, Chair Vice, Bozkurt Biykem, Butler Javed, Casey Donald E, Drazner Mark H, Fonarow Gregg C, Geraci Stephen A, Horwich Tamara, Januzzi James L, Johnson Maryl R, Kasper Edward K, Levy Wayne C, Masoudi Frederick A, Mcbride Patrick E, Mcmurray John J V, Mitchell Judith E, Peterson Pamela N, Riegel Barbara, Sam Flora, Stevenson Lynne W, Wilson Tang W H, Tsai Emily J, Bmcel Wilkoff Faccf, "2013 ACCF/AHA Guideline for the Management of Heart Failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, (20131015), vol. 62, no. 16, pages e147 - e239, XP093194310-
OPPOSITION- Yancy Clyde W, Jessup Mariell, Chair Vice, Bozkurt Biykem, Butler Javed, Casey Donald E, Drazner Mark H, Fonarow Gregg C, Geraci Stephen A, Horwich Tamara, Januzzi James L, Johnson Maryl R, Kasper Edward K, Levy Wayne C, Masoudi Frederick A, Mcbride Patrick E, Mcmurray John J V, Mitchell Judith E, Peterson Pamela N, Riegel Barbara, Sam Flora, Stevenson Lynne W, Wilson Tang W H, Tsai Emily J, Bmcel Wilkoff Faccf ;, "2013 ACCF/AHA Guideline for the Management of Heart Failure", Journal of the American College of Cardiology, (20131015), vol. 62, no. 16, pages e148 - e239, XP093197584-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, pages 784 - 785; 788, XP055751748-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, pages 784; - 785; 788, XP055751748-
OPPOSITION- Z. Kobalava et al., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (2011), vol. 32, XP055751748-
OPPOSITION- Heran Balraj S, Musini Vijaya M, Bassett Ken, Taylor Rod S, Wright James M, "Angiotensin receptor blockers for heart failure", Cochrane Database of Systematic Reviews, Wiley Interscience, US, US , (20120418), no. 3, doi:10.1002/14651858.CD003040.pub2, ISSN 1465-1858, XP093197677
OPPOSITION- Gustafsson, F. Steensgaard-Hansen, F. Badskjaer, J. Poulsen, A.H. Corell, P. Hildebrandt, P., "Diagnostic and Prognostic Performance of N-Terminal ProBNP in Primary Care Patients With Suspected Heart Failure", JOURNAL OF CARDIAL FAILURE., CHURCHILL LIVINGSTONE, NAPERVILLE, IL., US, US , (20050601), vol. 11, no. 5, doi:10.1016/j.cardfail.2005.04.022, ISSN 1071-9164, pages 15 - 20, XP004931253
OPPOSITION- Thomas H. Langenickel, William P.Dole, "Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure", Drug Discovery Today: Therapeutic Strategies, doi:10.1016/j.ddstr.2013.11.002, (20120101), pages e131 - e139, Drug Discovery Today: Therapeutic Strategies, (20201118), XP055751770
OPPOSITION- Maisel, A. ; Mueller, C. ; Adams, K. ; Anker, S.D. ; Aspromonte, N. ; Cleland, J.G.F. ; Cohen-Solal, A. ; Dahlstrom, U. ; DeMaria, A. ; Di Somma, S. ; Filippatos, G.S. ; Fonarow, G.C. ; Jourdain, P. ; Komajda, M. ; Liu, P.P. ; McDonagh, T. ; McDonald, K. ; Mebazaa, A. ; Nieminen, M.S. ; Peacock, W.F. ; Tubaro, M. ; Valle, R. ; Vanderhyden, M. ; Yancy, C.W. ; Zannad, F. ; Braunwald, E., "State of the art: Using natriuretic peptide levels in clinical practice", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20080901), vol. 10, no. 9, doi:10.1016/j.ejheart.2008.07.014, ISSN 1388-9842, pages 824 - 839, XP025427959
OPPOSITION- Masson Serge; Latini Roberto; Anand Inder S.; Barlera Simona; Angelici Laura; Vago Tarcisio; Tognoni Gianni; Cohn Jay N., "Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19000101), vol. 52, no. 12, doi:10.1016/j.jacc.2008.04.069, ISSN 0735-1097, pages 997 - 1003, XP029652181
OPPOSITION- Yancy Clyde W.; Jessup Mariell; Bozkurt Biykem; Butler Javed; Casey Donald E.; Drazner Mark H.; Fonarow Gregg C.; Geraci Stephen A.; Horwich Tamara; Januzzi James L.; Johnson Maryl R.; Kasper Edward K.; Levy Wayne C.; Masoudi Frederick A.; McBride Patrick E.; McMurray John J.V.; Mitchell Judith E.; Peterson Pamela N.; Riegel Barbara; Sam Flora; Stevenson Lynne W.; Tang W.H. Wilson; Tsai Emily J.; Wilkoff Bruce L., "2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines ", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130605), vol. 62, no. 16, doi:10.1016/j.jacc.2013.05.019, ISSN 0735-1097, XP028733857
OPPOSITION- Yancy Clyde W.; Jessup Mariell; Bozkurt Biykem; Butler Javed; Casey Donald E.; Colvin Monica M.; Drazner Mark H.; Filippatos Gerasimos S.; Fonarow Gregg C.; Givertz Michael M.; Hollenberg Steven M.; Lindenfeld JoAnn; Masoudi Frederick A.; McBride Patrick E.; Peterson Pamela N.; Stevenson Lynne Warner; Westlake Cheryl, "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20170428), vol. 70, no. 6, doi:10.1016/j.jacc.2017.04.025, ISSN 0735-1097, pages 776 - 803, XP085146786
OPPOSITION- Doron Aronson; Henry Krum;, "Novel therapies in acute and chronic heart failure", Pharmacology & Therapeutics, ELSEVIER., GB, GB , (20120701), vol. 135, no. 1, doi:10.1016/j.pharmthera.2012.03.002, ISSN 0163-7258, pages 1 - 17, XP028503167
OPPOSITION- Lili Feng; Piotr H. Karpinski; Paul Sutton; Yugang Liu; David F. Hook; Bin Hu; Thomas J. Blacklock; Philip E. Fanwick; Mahavir Prashad; Sven Godtfredsen; Christoph Ziltener;, "LCZ696: a dual-acting sodium supramolecular complex", Tetrahedron Letters, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (20111105), vol. 53, no. 3, doi:10.1016/j.tetlet.2011.11.029, ISSN 0040-4039, pages 275 - 276, XP028393477
OPPOSITION- Luis Miguel Ruilope, Andrej Dukat, Michael Böhm, Yves Lacourcière, Jianjian Gong, Martin P Lefkowitz,, "Blood-pressure reduction with LCZ696, a novel dueal-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100410), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, ISSN 0140-6736, pages 1255 - 1266, XP002676955
OPPOSITION- Luis Miguel Ruilope, "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", Lancet , (20100410), vol. 375, doi:10.1016/S0140-6736(09)61966-8, XP002676955
OPPOSITION- Luis Miguel Ruilope et al., "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", Lancet, (20100410), vol. 375, doi:10.1016/S0140-6736(09)61966-8, XP002676955
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, ¬J.B. Flint|, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562
OPPOSITION- Khalil Mohammed E, Basher Abul W, Brown Edward J, Alhaddad Imad A, "A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20010601), vol. 37, no. 7, doi:10.1016/S0735-1097(01)01229-3, ISSN 0735-1097, pages 1757 - 1764, XP093197711
OPPOSITION- Ferreira-Gonzalez, I. ; Alonso-Coello, P. ; Sola, I. ; Pacheco-Huergo, V. ; Domingo-Salvany, A. ; Alonso, J. ; Montori, V. ; Permanyer-Miralda, G., "Composite Endpoints in Clinical Trials", Revista Española de Cardiología (English Edition), ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20080101), vol. 61, no. 3, doi:10.1016/S1885-5857(08)60116-4, ISSN 1885-5857, pages 283 - 290, XP023783546
OPPOSITION- Shearer F, Lang C C, Struthers A D, "Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure", Clinical Pharmacology and Therapeutics, Nature Publishing Group, US, US , (20131001), vol. 94, no. 4, doi:10.1038/clpt.2013.135, ISSN 0009-9236, pages 459 - 467, XP093198094
OPPOSITION- O Vardeny et al., "First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure", Clinical Pharmacology & Therapeutics, (2013), vol. 94, doi:10.1038/clpt.2013.146, page 4, XP055224441
OPPOSITION- Lang Chim C., Struthers Allan D., "Targeting the renin-angiotensin-aldosterone system in heart failure", Nature Reviews Cardiology, Nature Publishing Group, GB, GB , (20130301), vol. 10, no. 3, doi:10.1038/nrcardio.2012.196, ISSN 1759-5002, pages 125 - 134, XP093195090
OPPOSITION- Crunkhorn Sarah, "Dual-acting combination meets heart failure end poin", Nature Reviews: Drug Discovery, (20121001), vol. 11, doi:10.1038/nrd3855, pages 740 - 740, XP093195133
OPPOSITION- Krum Henry; Tonkin Andrew, "Why do phase III trials of promising heart failure drugs often fail? the contribution of “regression to the truth”", JOURNAL OF CARDIAL FAILURE., CHURCHILL LIVINGSTONE, NAPERVILLE, IL., US, US , (20031001), vol. 9, no. 5, doi:10.1054/S1071-9164(03)00018-6, ISSN 1071-9164, pages 364 - 367, XP086087560
OPPOSITION- COHN J N, TOGNONI G, "A RANDOMIZED TRIAL OF THE ANGIOTENSIN-RECEPTOR BLOCKER VALSARTAN IN CHRONIC HEART FAILURE", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20011206), vol. 345, no. 23, doi:10.1056/NEJMoa010713, ISSN 1533-4406, pages 1667 - 1675, XP009033568
OPPOSITION- Chi Heem Wong, Kien Wei Siah, Andrew W Lo, "Estimation of clinical trial success rates and related parameters", Biostatistics, Oxford university press , Oxford, GB, GB , (20190430), vol. 20, no. 2, doi:10.1093/biostatistics/kxx069, ISSN 1465-4644, pages 273 - 286, XP055604937
OPPOSITION- Pascual-Figal Domingo A., Domingo Maite, Casas Teresa, Gich Ignasi, Ordoñez-Llanos Jordi, Martínez Pedro, Cinca Juan, Valdés Mariano, Januzzi James L., Bayes-Genis Antoni, "Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients", European Heart Journal, Oxford University Press, GB, GB , (20080401), vol. 29, no. 8, doi:10.1093/eurheartj/ehn023, ISSN 0195-668X, pages 1011 - 1018, XP093195182
OPPOSITION- J. J. V. Mcmurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M. A. Gomez-Sanchez, T. Jaarsma, L. Kober, G. Y. H. Lip, A. P. Maggioni, A. Parkhomenko, B. M. Pieske, B. A. Popescu, P. K. Ronnevik, F. H. Rutten, J. Schwitter, P. Seferovic, J. Stepinska, P. T. Trindade, A. A. Voors, F. Zannad, A. Zeiher, J. J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. Mcdonagh, C. Moulin, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, L. A. Bonet, P. Avraamides, H. A. Ben Lamin, M. Brignole, A. Coca, P. Cowburn, H. Dargie, P. Elliott, F. A. Flachskampf, G. F. Guida, S. Hardman, B. Iung, B. Merkely, C. Mueller, J. N. Nanas, O. W. Nielsen, S. Orn, J. T. Parissis, P. Ponikowski, "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC", European Heart Journal, No longer published by Elsevier, (20120702), vol. 33, no. 14, doi:10.1093/eurheartj/ehs104, ISSN 0195668X, pages 1787 - 1847, XP055140708
OPPOSITION- Mangiafico Sarah, Costello-Boerrigter Lisa C., Andersen Ingrid A., Cataliotti Alessandro, Burnett John C., "Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics", European Heart Journal, Oxford University Press, GB, GB , (20130321), vol. 34, no. 12, doi:10.1093/eurheartj/ehs262, ISSN 0195-668X, pages 886 - 893, XP055957205
OPPOSITION- Sarah Mangiafico et al., "Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics", European Heart Journal, (2013), vol. 34, doi:10.1093/eurheartj/ehs262, XP055957205
OPPOSITION- Sarah Mangiafico, "Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics", European Heart Journal, (2013), vol. 34, doi:10.1093/eurheartj/ehs262, XP055957205
OPPOSITION- Carlsen Christian Malchau, Bay Morten, Kirk Vibeke, Gøtze Jens Peter, Køber Lars, Nielsen Olav Wendelboe, "Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N‐terminal pro brain natriuretic peptide: a 10‐year analysis from the Copenhagen Hospital Heart Failure Study", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20120301), vol. 14, no. 3, doi:10.1093/eurjhf/hfs003, ISSN 1388-9842, pages 240 - 247, XP093195095
OPPOSITION- John J. V. McMurray, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparision of ARNI with ACEI to ...", European Journal of Heart Failure, (2013), vol. 15, doi:10.1093/eurjhf/hft052, XP055161544
OPPOSITION- John J.V. McMurray et al., "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparision of ARNI with ACEI to ...", European Journal of Heart Failure, (2013), vol. 15, doi:10.1093/eurjhf/hft052, XP055161544
OPPOSITION- John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OPPOSITION- Hegde, Laxminarayan G;- Yu, Cecile; Renner, Travis; Thibodeaux, Harold; Armstrong, Scott; Park, Timothy; Cheruvu, Madhavi; Olsufka, Rachael; Sandvik, Erik R; Lane, Cassie E; Budman, Joe; Hill, Craig M; Klein, Uwe; Hegde, Sharath S, "Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-Like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation In The Rat", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, US , doi:10.1097/FJC.0b013e318210fc7e, ISSN 0160-2446, pages 1 - 43, XP008134877
OPPOSITION- Gaggin Hanna K., Truong Quynh A., Rehman Shafiq U., Mohammed Asim A., Bhardwaj Anju, Parks Kimberly A., Sullivan Dorothy A., Chen‐tournoux Annabel, Moore Stephanie A., Richards A. Mark, Troughton Richard W., Lainchbury John G., Weiner Rory B., Baggish Aaron L., Semigran Marc J., Januzzi James L., "Characterization and Prediction of Natriuretic Peptide “Nonresponse”During Heart Failure Management: Results From the ProBNP OutpatientTailored Chronic Heart Failure (PROTECT) and the NT-proBNP-AssistedTreatment to Lessen Serial Cardiac Readmissions and Death(BATTLESCARRED) Study", CONGESTIVE HEART FAILURE, CHF INC., GREENWICH, CT, US, US , (20130501), vol. 19, no. 3, doi:10.1111/chf.12016, ISSN 1527-5299, pages 135 - 142, XP093198086
OPPOSITION- Doust Jenny A, Pietrzak Eva, Dobson Annette, Glasziou Paul, "How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review", BMJ, BMJ, (20050319), vol. 330, no. 7492, doi:10.1136/bmj.330.7492.625, ISSN 0959-8138, page 625, XP093198046
OPPOSITION- Packer Milton, Califf Robert M., Konstam Marvin A., Krum Henry, Mcmurray John J., Rouleau Jean-Lucien, Swedberg Karl, "Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure : The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)", Circulation, American Heart Association, US, US , (20020820), vol. 106, no. 8, doi:10.1161/01.CIR.0000029801.86489.50, ISSN 0009-7322, pages 920 - 926, XP093195122
OPPOSITION- Yancy Clyde W, Yancy Clyde W, Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey, Drazner Mark H, Fonarow Gregg C, Geraci Stephen A, Horwich Tamara, Januzzi James L, Johnson Maryl R, Kasper Edward K, Levy Wayne C, Masoudi Frederick A, Mcbride Patrick E, Mcmurray John, Mitchell Judith E, Peterson Pamela N, Riegel Barbara, Sam Flora, Stevenson Lynne W, Tang W, Tsai Emily J, Wilkoff Bruce L, "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines", Circulation, American Heart Association, US, US , (20131015), vol. 62, no. 16, doi:10.1161/CIR.0b013e31829e8776, ISSN 0009-7322, pages e147 - e239, XP093180312
OPPOSITION- Wessler Benjamin S., Kramer Daniel G., Kelly Jessica L., Trikalinos Thomas A., Kent David M., Konstam Marvin A., Udelson James E., "Drug and Device Effects on Peak Oxygen Consumption, 6-Minute Walk Distance, and Natriuretic Peptides as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction", Circulation. Heart Failure, Lippincott Williams & Wilkins, US, US , (20110901), vol. 4, no. 5, doi:10.1161/CIRCHEARTFAILURE.111.961573, ISSN 1941-3289, pages 578 - 588, XP093197680
OPPOSITION- Von Lueder, Et Al, "Renin-Angiotensin Blockade Combined with Natriuretic Peptide System Augmentation", Circ. Heart Fail, (20130101), vol. 6, doi:10.1161/CIRCHEARTFAILURE.112.000289, pages 594 - 605, XP055780114
OPPOSITION- Fanaroff Alexander C., Clare Robert, Pieper Karen S., Mahaffey Kenneth W., Melloni Chiara, Green Jennifer B., Alexander John H., Jones W. Schuyler, Harrison Robert W., Mehta Rajendra H., Povsic Thomas J., Moreira Humberto G., Al-Khatib Sana M., Roe Matthew T., Kong David F., Mathews Robin, Tricoci Pierluigi, Holman Rury R., Wallentin Lars, Held Claes, Califf Robert M., Alexander Karen P., Lopes Renato D., "Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials", Circulation, American Heart Association, US, US , (20190212), vol. 139, no. 7, doi:10.1161/CIRCULATIONAHA.118.037202, ISSN 0009-7322, pages 863 - 873, XP093195423
OPPOSITION- Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel D F, Jeng A Y, Lin T H, Zheng W, Dole W P, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", Journal of clinical pharmacology, Wiley-Blackwell Publishing, Inc., US, US , (20100401), vol. 50, no. 4, doi:10.1177/0091270009343932, ISSN 1552-4604, pages 401 - 414, XP002718352
OPPOSITION- Jessie Gu et al., "Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)", Journal of Clinical Pharmacology, (2010), vol. 50, doi:10.1177/0091270009343932, XP002718352
OPPOSITION- Martin P Lefkowitz, "LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension", BMC PHARMACOLOGY, BIOMED CENTRAL, LONDON, GB, GB , (20110801), vol. 11, no. Suppl 1, doi:10.1186/1471-2210-11-S1-O3, ISSN 1471-2210, page O3, XP021104814
OPPOSITION- Chrysant, Steven G., "LCZ-696: angiotensin AT, receptor antagonist/neprilysin inhibitor treatment of heart failure treatment of hypertension", Drugs of the Future, Prous Science, ES, ES , (20110301), vol. 36, no. 3, doi:10.1358/dof.2011.36.3.1588061, ISSN 0377-8282, pages 183 - 190, XP009173432
OPPOSITION- Segura Julian, Salazar Jorge, Ruilope Luis M, "Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20131101), vol. 22, no. 7, doi:10.1517/13543784.2013.797962, ISSN 1354-3784, pages 915 - 925, XP093197689
OPPOSITION- Voors A A; Dorhout B; Van Der Meer P, "The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20130101), vol. 22, no. 8, doi:10.1517/13543784.2013.797963, ISSN 1354-3784, pages 1041 - 1047, XP009173461
OTHER- Anonymous, "PARADIGM-HF trial stopped early for benefit", European Society of Cardiology The ESC ESC Press Office Press releases, (20040516), pages 1 - 4, European Society of Cardiology The ESC ESC Press Office Press releases, URL: https://www.escardio.org/The-ESC/Press-Office/Press-releases/PARADIGM-HF-trial-stopped-early-for-benefit, (20220117), XP055879620-
OTHER- Forth W., D. Henschler Und W. Rummel, "Allgemeine und spezielle Pharmakologie und Toxikologie", Allgemeine und spezielle Pharmakologie und Toxikologie, 9., völlig überarbeitete Auflage, München, Jena, URBAN & FISCHER, Elsevier, (20050101), pages 92 - 422-433, XP093040425-
OTHER- Jordaan P, Et Al, "Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment", SA Heart Congress 2011, (20110101), page 236, XP055780447-
OTHER- Kobalava Z. et al, "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term /c treatment with LCZ696 in heart failure patients: effect (8) on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, P4396, (20110101), pages 784 - 785, XP093040441-
OTHER- Kobalava Z. et al, "P4409 Clinic blood pressure in stables heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696", European Heart Journal, (20110101), page 788, XP055891073-
OTHER- Valsartan, "Prescribing information for Diovan", VALSARTAN, (20120101), pages 1 - 20, XP093093489-
OTHER- Yancy Clyde W.; Jessup Mariell; Bozkurt Biykem; Butler Javed; Casey Donald E.; Drazner Mark H.; Fonarow Gregg C.; Geraci Stephen A.; Horwich Tamara; Januzzi James L.; Johnson Maryl R.; Kasper Edward K.; Levy Wayne C.; Masoudi Frederick A.; McBride Patrick E.; McMurray John J.V.; Mitchell Judith E.; Peterson Pamela N.; Riegel Barbara; Sam Flora; Stevenson Lynne W.; Tang W.H. Wilson; Tsai Emily J.; Wilkoff Bruce L., "2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines ", Journal of the American College of Cardiology, AMSTERDAM, NL, (20130605), vol. 62, no. 16, doi:10.1016/j.jacc.2013.05.019, ISSN 0735-1097, pages 1 - 93, XP028733857
OTHER- Doron Aronson; Henry Krum;, "Novel therapies in acute and chronic heart failure", Pharmacology & Therapeutics, GB , (20120701), vol. 135, no. 1, doi:10.1016/j.pharmthera.2012.03.002, ISSN 0163-7258, pages 1 - 17, XP028503167
OTHER- Chi Heem Wong, Kien Wei Siah, Andrew W Lo, "Estimation of clinical trial success rates and related parameters", Biostatistics, GB , (20190430), vol. 20, no. 2, doi:10.1093/biostatistics/kxx069, ISSN 1465-4644, pages 273 - 286, XP055604937
OTHER- J. J. V. Mcmurray et al, "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012", European Heart Journal, No longer published by Elsevier, (20120702), vol. 33, no. 14, doi:10.1093/eurheartj/ehs104, ISSN 0195668X, pages 1787 - 1847, XP055140708
OTHER- Mangiafico Sarah, Costello-Boerrigter Lisa C., Andersen Ingrid A., Cataliotti Alessandro, Burnett John C., "Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics", European Heart Journal, GB , (20130321), vol. 34, no. 12, doi:10.1093/eurheartj/ehs262, ISSN 0195-668X, pages 886 - 893, XP055957205
OTHER- John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, NL , (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OTHER- Voors A A; Dorhout B; Van Der Meer P, "The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure", Expert Opinion on Investigational Drugs, UK , (20130101), vol. 22, no. 8, doi:10.1517/13543784.2013.797963, ISSN 1354-3784, pages 1041 - 1047, XP009173461
OTHER- Sabe Marwa A, Jacob Miriam S, Taylor David O, "A new class of drugs for systolic heart failure: The PARADIGM-HF study", CLEVELAND CLINIC JOURNAL OF MEDICINE, (20151001), vol. 82, no. 10, doi:10.3949/ccjm.82a.14163, pages 693 - 701, XP093197153
SEARCH- DORON ARONSON ET AL, "Novel therapies in acute and chronic heart failure", PHARMACOLOGY AND THERAPEUTICS, vol. 135, no. 1, doi:10.1016/J.PHARMTHERA.2012.03.002, ISSN 0163-7258, (20120323), pages 1 - 17, (20120323), XP028503167 [A] 1-15 * the whole document *
SEARCH[ ] - CHI HEEM WONG ET AL, "Estimation of clinical trial success rates and related parameters", BIOSTATISTICS, GB, (20190401), vol. 20, no. 2, doi:10.1093/biostatistics/kxx069, ISSN 1465-4644, pages 273 - 286, XP055604937 [ ] * page 279; table 2 * * figure 1 *
SEARCH- JOHN J. V. MCMURRAY ET AL, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, (20130504), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544 [A] 1-15 * the whole document *
SEARCH- VOORS A A ET AL, "The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, (20130101), vol. 22, no. 8, doi:10.1517/13543784.2013.797963, ISSN 1354-3784, pages 1041 - 1047, XP009173461 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents